Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Century Therapeutics (IPSC) Non Operating Income (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Non Operating Income for 4 consecutive years, with -$181000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 97.3% to -$181000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2025, up 1149.44% year-over-year, with the annual reading at -$9000.0 for FY2025, 102.54% down from the prior year.
  • Non Operating Income for Q4 2025 was -$181000.0 at Century Therapeutics, down from $97000.0 in the prior quarter.
  • The five-year high for Non Operating Income was $3.6 million in Q2 2024, with the low at -$6.7 million in Q4 2024.
  • Average Non Operating Income over 4 years is $663812.5, with a median of $173500.0 recorded in 2024.
  • Peak annual rise in Non Operating Income hit 1983.33% in 2024, while the deepest fall reached 44660.0% in 2024.
  • Over 4 years, Non Operating Income stood at $3.0 million in 2022, then crashed by 100.5% to -$15000.0 in 2023, then plummeted by 44660.0% to -$6.7 million in 2024, then soared by 97.3% to -$181000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$181000.0, $97000.0, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.